45 WIGGINS AVENUE, BEDFORD, MA
News, Material Contracts
Amended material disclosure
Reports Second Quarter 2025 Financial Results and Provides Business Updates
Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Submission of Matters to a Vote of Security Holders
Investor Presentation
Reports First Quarter 2025 Financial Results and Provides Business Updates
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities